

MINUTES
INSTITUTIONAL BIOSAFETY COMMITTEE
DATE: July 10, 2026

Attendance: Total Attending: 8

Voting Members Present: 7

Called to Order: 10:00 a.m.

Name	Expertise	Present
Linda Cassidy, MS	Non-Voting Member	X
Sue Gotta, MS	rDNA; Select Agents	
Gerald Grunwald, PhD	rDNA; Biochemistry; Cellular & Developmental Biology	X
Botond Igyarto, PhD	Microbiology	X
Loretta Kelly, Esq.	Non-affiliate Community Member	X
Kathleen “Kitty” Kono	Non-Affiliate Community Member	X
Phil LaTourette, DVM	Laboratory Animal Sciences	X
Sara Meyer, PhD	Cancer Biology	
Fabienne Paumet, PhD	Cellular Biology & Biochemistry	X
Drake Stierman	Safety Officer	
Megan Watson, MS	Lab Specialist	X

MINUTES REVIEWED:

Minutes of the June 12, 2026 meeting were presented for review.

Motion to Approve: Kitty Kono

Seconded: Loretta Kelly

Total = #7; For-#6, Opposed-#0, Abstained-#1

NEW PROTOCOLS:

1. Principal Investigator L.D.

IBC Control# 26-06-1035

Summary:

- This protocol is evaluating the efficacy of ultrasound-triggered antibacterial/antimicrobial release from a hydrogel in surgical site infections.
- This is an in vitro and in vivo study.
- The principal risks identified were:
 - *Staphylococcus aureus*
 - *Cutibacterium acnes*
 - *Staphylococcus epidermidis*
 - Methicillin-sensitive *Staphylococcus aureus*
 - USA300 Methicillin-resistant *Staphylococcus aureus*
- Containment has been set to BSL-2 and ABSL-2.

Committee Review:

- This protocol did not involve either recombinant or synthetic DNA.
- The risks were adequately identified by the Principal Investigator and appropriate mitigation was described in the protocol.

- Clarifications were requested.
- A motion was made and seconded to provisionally approve this protocol. The motion was unanimously approved.

ADMINISTRATIVELY APPROVED ITEMS:

The KSI database indicates the following items have been given administrative approval since our last meeting:

July 10, 2026

24-07-871	MD	Continuing Review	Active - questions related to database update answered
23-01-627-1	MT	Amendment	Added nanoparticle, updated personnel & research location
22-06-510-1	QL	Continuing Review	Not started - questions related to database update answered
21-10-445-1	FI	Continuing Review	Active - added 2 chemicals & questions related to database update answered
21-06-395-1	JM	Continuing Review	Active - questions related to database update answered
24-05-846	JM	Continuing Review	Active - questions related to database update answered
21-04-370-1	JM	Continuing Review	Active - questions related to database update answered
22-01-472-1	LH	Continuing Review	Active - questions related to database update answered
26-04-1027	BC	New	Work with human cells and chemotherapeutics

OTHER BUSINESS:

- The committee agreed for gene therapy clinical trials involving CAR-T cells, only the CAR-T cells need to be listed in Question 1 of the recombinant DNA page of the protocol. The vector does not have to be listed if the cells are manipulated off-site.

Meeting Adjourned: 10:18 a.m.

Respectfully submitted for the IBC,

/s/Gerald Grunwald, PhD

Chair, Institutional Biosafety Committee

GG/lc